Beranda › Kanker Laring › Idaho › Boise
Uji klinis Kanker Laring di Boise, ID
4 studi untuk Kanker Laring mencari peserta di lokasi sekitar Boise (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Menerima pesertaFase 3
- Saint Alphonsus Cancer Care Center-Boise, Boise
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Menerima pesertaFase 2
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Menerima pesertaFase 2
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Boise
Uji klinis Kanker Laring di kota lain
- Atlanta, GA8 studi
- Chicago, IL8 studi
- Milwaukee, WI8 studi
- Kansas City, MO7 studi
- Portland, OR7 studi
- St. Louis, MO7 studi
- Cincinnati, OH6 studi
- Richmond, VA6 studi
- Edison, NJ6 studi
- Baltimore, MD6 studi
- Pittsburgh, PA6 studi
- Durham, NC6 studi
Studi lain di Boise
- Kanker Paru Non-Sel Kecil14 studi
- Kanker Paru11 studi
- Leukemia Mieloid Akut8 studi
- Kanker Prostat8 studi
- Kanker Kolon7 studi
- Kanker Kolorektal6 studi
- Sindrom Distres Respirasi6 studi
- Kanker Payudara6 studi
- Melanoma6 studi
- Limfoma Burkitt5 studi
- Kanker Pankreas4 studi
- Neoplasma Mieloproliferatif4 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.